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As spelled out in the title of our paper,1 it was the aim of our study to present long-term results of percutaneous transluminal laser angioplasty (PTLA). Our results show a 36-month patency rate of 63%. This was a novel observation, resulting in publication in the journal and an accompanying editorial. We did not attempt to compare PTLA with any other treatment modality, but we do agree with Dr. Hartnell that this should be the next step in evaluating the true benefit of such treatment.
Dr. Hartnell points out that in his hands, the use of the guide wire alone may result in a primary success rate of up to 97%. Such results, although not the subject of our study, are of great interest, and we look forward to seeing full publication in a peer-reviewed journal. Again, Dr. Hartnell is not giving long-term results; also, the two studies that he wants us to quote pertain to primary success rate and not to long-term patency.
As discussed in our article, we neither used the guide wire very aggressively nor applied a very stiff or hydrophilic guide wire. Aggressive use of the guide wire in our study could have jeopardized the subsequent use of PTLA.
We are happy to report that a randomized, controlled clinical trial between PTLA and percutaneous transluminal angioplasty as suggested by Dr. Hartnell is now nearing completion in our laboratory and will be reported in due time. In their interesting article,1 Dr. Sane et al compared responses to thrombolytic therapy in black and white patients with acute myocardial infarction. They noticed that black patients had an apparent enhanced sensitivity to rt-PA manifested by increased thrombolytic efficacy, a more pronounced systemic fibrinogen breakdown, and increased transfusions. The authors speculated that differences might exist in the hepatic clearance of rt-PA between blacks and whites. I suggest that the data of Dr. Sane et al can be explained by racial differences in resting blood fibrinolytic activity. Gillman et a12 and Merskey et a13 were the first to report higher fibrinolytic activity in African than in European men. These results were subsequently confirmed by a number of authors.4 Such differences were due to racial rather than cultural or environmental factors. In black and white Americans living in the same county of southern Georgia, blacks exhibited a significant increase in fibrinolysis at rest in comparison with whites.5 Blacks had higher whole plasma fibrinolytic activity, higher content of plasminogen in euglobulins, and lower antiplasmin levels. Under such circumstances, the same stimulus (e.g., t-PA) might be expected to raise fibrinolytic activity to higher levels in blacks than in whites. Indeed, Howell4 found greater fibrinolytic activity in whole plasma of Nigerians than Europeans and also showed that Nigerians had a greater response to stimulation by intravenous nicotinic acid.
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